A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Excerpt | Reference |
|---|
| "Idiopathic pulmonary fibrosis is a fatal disorder that starts as an alveolitis and progresses to interstitial fibrosis." | ( Crystal, RG; Fulmer, JD; Line, BR; Moss, ML; Reynolds, HY; Roberts, WC, 1976) |
| "Pulmonary fibrosis is a crippling, essentially lethal chronic disease due to an interplay of events following irradiation between the pneumonitic and fibrotic phases." | ( Finkelstein, J; Rubin, P; Shapiro, D, 1992) |
| "Idiopathic pulmonary fibrosis is an immunologically mediated pulmonary disorder in which activated alveolar macrophages (AM) and neutrophils play cardinal roles in the pathogenesis of the inflammatory lung lesion." | ( Kunkel, SL; Lynch, JP; Rolfe, MW; Standiford, TJ; Strieter, RM, 1992) |
| "Pulmonary fibrosis is an irreversible accumulation of connective tissue in the interstitium of the lung." | ( Greenberg, AH; Khalil, N, 1991) |
| "Idiopathic pulmonary fibrosis is an inexorably fatal disorder characterized by connective tissue deposition within the terminal air spaces resulting in loss of lung function and eventual respiratory failure." | ( Broekelmann, TJ; Colby, TV; Limper, AH; McDonald, JA, 1991) |
| "Pulmonary fibrosis is a serious side effect of nitrosourea therapy, occurring most frequently in patients treated with BCNU." | ( Block, M; Hirschl, S; Lachowiez, RM; Rios, C, 1990) |
| "Idiopathic pulmonary fibrosis is one of the few nonembolic diseases producing a pulmonary ventilation-perfusion mismatch." | ( Almagro, UA; Collier, BD; Hellman, RS; Isitman, AT; Krasnow, AZ; Mewissen, MW; Pochis, WT, 1990) |
| "Idiopathic pulmonary fibrosis is characterized by an inflammation of the walls of the respiratory airspaces that proceed to fibrotic alveolar derangement." | ( Bernaudin, JF; Bignon, J; Brochard, P; de Cremoux, H; Laurent, P, 1990) |
| "Interstitial pulmonary fibrosis is characterized by an abnormal accumulation of fibroblasts with a resultant increase in lung collagen content." | ( Lindenschmidt, RC; Sendelbach, LE; Witschi, HP, 1985) |
| "Interstitial pulmonary fibrosis is a serious complication of inflammatory muscle disease associated with significant morbidity and mortality." | ( al-Janadi, M; Karsh, J; Smith, CD, 1989) |
| "Pulmonary fibrosis is the end point of progressive functional disorder of respiratory mechanism and alveolo-capillary gas exchanges." | ( Butti, G; Gaetani, P; Knerich, R; Rossi, A; Silvani, V; Spanu, G, 1987) |
| "Pulmonary fibrosis is characterized by an alteration in lung collagen synthesis and deposition, as well as by increased fibroblast proliferation." | ( Gauldie, J; Jordana, M; Newhouse, MT, 1987) |
| "Pulmonary fibrosis is a consequence of severe injury from some toxic agents including high doses of ozone." | ( Kehrer, JP; Smiler, KL; White, DM; Wright, ES, 1988) |
| "The severity of pulmonary fibrosis is not associated with rheumatologic symptoms or the duration of the associated RA, nor is there any clear relation to the extraarticular features of RA or serologic findings." | ( Roschmann, RA; Rothenberg, RJ, 1987) |
| "Interstitial pulmonary fibrosis is described in a 26-year-old woman with malignant lymphoma after prolonged intake of cyclophosphamide." | ( Abdel Karim, FW; Allam, C; Ayash, RE; Salem, PA, 1983) |
| "Pulmonary fibrosis is a previously unreported complication of amiodarone therapy." | ( Rakita, L; Sobol, SM, 1982) |
| "Bleomycin-induced pulmonary fibrosis is associated with increased lung transforming growth factor-beta (TGF-beta) gene expression, but cellular localization of the source of this expression has not been unequivocally established." | ( Flanders, KC; Phan, SH; Zhang, K, 1995) |
| "Pre-existing pulmonary fibrosis is an independent risk factor for accelerated annual decline of FEV1, even when mild and stable." | ( Nakadate, T, 1995) |
| "Pulmonary fibrosis is a common feature of systemic sclerosis (SSc) and a major cause of morbidity and mortality." | ( Akesson, A; Lundin, A; Scheja, A; Wollheim, FA, 1994) |
| "Interstitial pulmonary fibrosis is characterized by increased production of connective tissue components, including collagen and elastin." | ( Agarwal, A; Goldstein, RH; Lucey, EC; Ngo, HQ; Smith, BD; Snider, GL, 1996) |
| "Pulmonary fibrosis is a frequent and serious complication of scleroderma whose pathophysiology remains poorly understood." | ( Aubier, M; Crestani, B, 1996) |
| "Pulmonary fibrosis is a disorder causing a high mortality rate for which therapeutic options are limited." | ( Cotev, S; Feferman, R; Firman, N; Nagler, A; Pines, M; Shoshan, S, 1996) |
| "Pulmonary fibrosis is the common end stage of a number of pneumopathies." | ( Amento, EP; Erikson, ME; Grove, BH; Pickford, LB; Piercy, CE; Salles, AL; Unemori, EN, 1996) |
| "The prognosis of pulmonary fibrosis is poor and current therapies inadequate." | ( Coker, RK; Laurent, GJ, 1997) |
| "Since pulmonary fibrosis is a recognized, if rare, complication of certain drug exposures, including antidepressants, betablockers, antibiotics, anticonvulsants, and nonsteroidal antiinflammatory drugs (NSAIDs), we tested the hypothesis that exposure to these drugs might contribute to the etiology of cryptogenic fibrosing alveolitis." | ( Britton, J; Cooper, M; Hubbard, R; Johnston, I; Smith, C; Venn, A, 1998) |
| "Pulmonary fibrosis is the pathological result of a diverse group of insults." | ( Christensen, PJ; Goodman, RE; Moore, B; Pastoriza, L; Toews, GB, 1999) |
| "Pulmonary fibrosis is a disabling consequence of many lung diseases but is difficult to quantify." | ( Antonini, JM; Davis, GS; Hemenway, DR, 2000) |
| "Pulmonary fibrosis is initiated by migration, adhesion, and proliferation of fibroblasts." | ( Fukuchi, Y; Ienaga, H; Kon, S; Maeda, K; Maeda, M; Okazaki, T; Takahashi, F; Takahashi, K; Uede, T, 2001) |
| "Pulmonary fibrosis is a chronic progressive disease with no effective therapy." | ( Galt, T; Gauldie, J; Kolb, M; Margetts, PJ; Schmidt, M; Sime, PJ; Xing, Z, 2001) |
| "Bleomycin-induced pulmonary fibrosis is known to be associated with the increased activity of two gelatinases, matrix metalloproteinase (MMP)-2 and MMP-9, in bronchoalveolar lavage (BAL)." | ( Boichot, E; Caulet-Maugendre, S; Corbel, M; Germain, N; Lagente, V; Molet, S, 2001) |
| "Pulmonary fibrosis is a progressive and largely untreatable group of disorders that affects up to 100,000 people on any given day in the United States." | ( Allard, J; Ben-Dor, A; DeLustro, B; Eugui, E; Heller, RA; Kaminski, N; Kim, Y; Lollini, L; Morris, D; Pardo, A; Selman, M; Sheppard, D; Yakhini, Z; Zuo, F, 2002) |
| "Pulmonary fibrosis is an interstitial disorder of the lung parenchyma whose mechanism is poorly understood." | ( Ishii, S; Kita, Y; Nagase, T; Ohga, E; Ouchi, Y; Shimizu, T; Uozumi, N; Yamamoto, H, 2002) |
| "Pulmonary fibrosis is a serious lung disorder that in certain cases may be difficult to quantify." | ( Antonini, JM; Hubbs, AF; Reasor, MJ; Roberts, JR; Taylor, MD, 2002) |
| "Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix proteins within the pulmonary interstitium." | ( Chambers, RC; Egan, JJ; Goldsack, NR; Hasleton, PS; Howell, DC; Laurent, GJ; Marshall, RP; Simler, NR, 2002) |
| "Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix in the interstitium, resulting in impaired lung function and respiratory failure." | ( Bonniaud, P; Galt, T; Gauldie, J; Kelly, MM; Kolb, M; Margetts, PJ; Sime, PJ, 2002) |
| "Idiopathic pulmonary fibrosis is typically seen in older individuals." | ( Aggarwal, AN; Jindal, SK; Sharma, CP; Vashisht, K, 2002) |
| "Interstitial pulmonary fibrosis is a recognized complication of DM, often correlated with antisynthetase enzymes, such as anti-Jo-1." | ( Cohen, JB; Costner, MI; High, WA; Murphy, BA, 2003) |
| "Pulmonary fibrosis is a major cause of death in scleroderma patients." | ( Atamas, SP; Choi, J; Luzina, IG; White, B; Wigley, FM; Wise, R; Xiao, HQ, 2003) |
| "Pulmonary fibrosis is associated with a poor prognosis." | ( Atzori, L; Barbarisi, M; Chua, F; Dunsmore, SE; Laurent, GJ; McAnulty, RJ; Willis, D, 2004) |
| "As pulmonary fibrosis is not spontaneously observed in ep mice, we hypothesized that external stimuli are necessary for the genetic predisposition of its development." | ( Fukuchi, Y; Hosokawa, Y; Ishidoh, K; Kominami, E; Kumasaka, T; Mitani, K; Yoshioka, Y, 2004) |
| "Pulmonary fibrosis is an end-stage disorder for which efficacious therapeutic options are not readily available." | ( Hegab, AE; Ishii, Y; Kimura, T; Mochizuki, M; Morishima, Y; Nomura, A; Sakamoto, T; Sekizawa, K; Shibuya, A; Shibuya, K; Taniguchi, M, 2004) |
| "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy." | ( Chen, CL; Chiu, CF; Chow, KC; Liaw, YC; Shen, YC; Yeh, SP, 2004) |
| "The pathogenesis of pulmonary fibrosis is thought to involve alveolar epithelial injury that, when successfully repaired, can limit subsequent scarring." | ( Christensen, PJ; Du, M; Hansen, JM; Hanson, KE; Lazar, MH; Simon, RH; Sisson, TH; Subbotina, NM; White, ES; Yu, B, 2004) |
| "Pulmonary fibrosis is the result of abnormal processes of repair that occur after lung injury." | ( Abe, S; Azuma, A; Hashimoto, S; Henmi, S; Izawa, A; Kudoh, S; Li, YJ; Matsuda, K; Miyauchi, Y; Sone, S; Ueda, K; Usuki, J, 2005) |
| "Pulmonary fibrosis is characterized by chronic scar formation and deposition of extracellular matrix, resulting in impaired lung function and respiratory failure." | ( Bonniaud, P; Chakravarty, S; Damm, D; Dugar, S; Gauldie, J; Higgins, L; Kapoun, AM; Kolb, M; Margetts, PJ; Murphy, A; Protter, AA; Schroeder, JA, 2005) |
| "Idiopathic pulmonary fibrosis is an incurable fibrosing disorder that progresses relentlessly to respiratory failure." | ( Alber, S; Choi, AM; Fattman, CL; Greenhill, S; Morse, D; Oury, TD; Song, R; Zhou, Z, 2005) |
| "Pulmonary fibrosis is characterized by a loss of lung epithelial cells, replaced by interstitial myofibroblasts to deposit extracellular matrix (ECM) proteins." | ( Li, MY; Matsumoto, K; Mizuno, S; Nakamura, T, 2005) |
| "Pulmonary fibrosis is a progressive life-threatening disease for which no effective therapy exists." | ( Burgess, HA; Daugherty, LE; Lakatos, HF; Phipps, RP; Ray, DM; Redonnet, M; Sime, PJ; Thatcher, TH, 2005) |
| "Idiopathic pulmonary fibrosis is characterised by the presence of active eosinophilic airway inflammation raising the possibility that airway inflammation may contribute to symptoms such as cough." | ( Birring, SS; Bradding, P; Brightling, CE; Hargadon, B; McKenna, S; Parker, D; Pavord, ID, 2005) |
| "Pulmonary fibrosis is a common feature of numerous lung disorders, including interstitial lung diseases, asthma, and chronic obstructive pulmonary disease." | ( Blackburn, MR; Chunn, JL; Kellems, RE; Mi, T; Molina, JG; Xia, Y, 2005) |
| "Pulmonary fibrosis is a progressive scarring disease of the lung." | ( Barth, RK; Sime, PJ; Thatcher, TH, 2005) |
| "Pulmonary fibrosis is a progressive illness characterized by interstitial fibrosis." | ( Chung, DH; Chung, JH; Kim, HY; Kim, JH; Kim, S; Park, WS, 2005) |
| "Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis." | ( Behr, J; Buhl, R; Capron, F; Corvasce, G; Costabel, U; De Vuyst, P; Dekhuijzen, R; Demedts, M; Flower, CD; Jansen, HM; Lankhorst, I; Laurent, F; MacNee, W; Montanari, M; Nicholson, AG; Petruzzelli, S; Rodriguez-Becerra, E; Sardina, M; Thomeer, M; van den Bosch, JM; Verbeken, EK; Verschakelen, J; Wallaert, B, 2005) |
| "The mechanisms of pulmonary fibrosis are complex, and several hypotheses have been put forward to explain how fibrosis develops." | ( Belperio, JA; Keane, MP; Strieter, RM, 2005) |
| "Idiopathic pulmonary fibrosis is the most common form of the interstitial lung diseases and is characterized by chronic progressive pulmonary parenchymal fibrosis." | ( Allen, J; Baran, CP; Bhatt, N; Magro, C; Marsh, CB, 2006) |
| "Idiopathic pulmonary fibrosis is a chronic diffuse lung disease of unknown cause, and a risk factor for increasing morbidity and mortality after lung resection." | ( Ahiskali, R; Bostanci, K; Kodalli, N; Ozyurtkan, MO; Yüksel, M, 2006) |
| "Idiopathic pulmonary fibrosis is a devastating disorder for which there is no effective treatment." | ( Dohi, M; Miyazaki, J; Nakagome, K; Okunishi, K; Tanaka, R; Yamamoto, K, 2006) |
| "Idiopathic pulmonary fibrosis is a fatal disease with a variable rate of progression." | ( Andrei, AC; Colby, TV; Flaherty, KR; Fraley, C; Gross, BH; Kazerooni, EA; Lama, V; Martinez, FJ; Murray, S; Toews, GB; Travis, WD, 2006) |
| "Pulmonary fibrosis is characterized by progressive worsening in pulmonary function leading to high incidence of death." | ( Kadokawa, Y; Kubo, H; Mishima, M; Okoshi, K; Sakai, Y; Tabata, C; Tabata, R; Takahashi, M, 2006) |
| "Pulmonary fibrosis is a leading cause of death in systemic sclerosis (SSc)." | ( Bolster, M; Clements, PJ; Connelly, K; Elashoff, R; Furst, DE; Goldin, J; Mayes, MD; Metersky, M; Roth, MD; Schraufnagel, D; Seibold, JR; Silver, RM; Simms, RW; Steen, V; Sterz, M; Tashkin, DP; Wise, RA, 2007) |
| "Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix in interstitium resulting in respiratory failure associated with inflammation showing mainly neutrophil (PMN) recruitment." | ( Boichot, E; Guénon, I; Lagente, V; Manoury, B; Nénan, S, 2007) |
| "Pulmonary fibrosis is a common response to a variety of lung injuries, characterized by fibroblast/myofibroblast expansion and abnormal accumulation of extracellular matrix." | ( Arreola, JL; Cabrera, S; D'Armiento, J; Gaxiola, M; Jara, P; Pardo, A; Ramírez, R; Richards, T; Selman, M, 2007) |
| "Pulmonary fibrosis is thought to be closely associated with the T-helper type-2 (Th2) immune response." | ( Bando, M; Gejyo, F; Moriyama, H; Ohno, S; Sugiyama, Y; Suzuki, E; Tajima, S; Takada, T; Terada, M; Yamasawa, H, 2007) |
| "Human pulmonary fibrosis is characterized by alveolar epithelial cell injury, areas of type II cell hyperplasia, accumulation of fibroblasts and myofibroblasts, and the deposition of extracellular matrix proteins." | ( Hogaboam, CM; Moore, BB, 2008) |
| "Pulmonary fibrosis is characterized by the accumulation of fibroblasts and myofibroblasts." | ( Charbeneau, RP; McMillan, TR; Moore, BB; Peters-Golden, M; Thomas, PE; Toews, GB; Vannella, KM; Wilke, CA, 2007) |
| "Indeed, pulmonary fibrosis is a major cause of death in SSc." | ( Abraham, DJ; Black, CM; Bou-Gharios, G; Denton, CP; du Bois, RM; Kennedy, L; Leask, A; Renzoni, EA; Shi-wen, X, 2007) |
| "Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling." | ( Gangireddy, SR; Hogaboam, CM; Hu, B; Keshamouni, VG; Milam, JE; Phan, SH; Reddy, RC; Standiford, TJ; Thannickal, VJ, 2008) |
| "Idiopathic pulmonary fibrosis is a progressive disease with high mortality." | ( Christensen, PJ; Fields, WB; McMillan, TR; Moore, BB; Toews, GB; van Dyk, LF; Vannella, KM; Weinberg, JB, 2008) |
| "Pulmonary fibrosis is the result of interactions between many effector cells and cytokines and better understanding of this can help with identification of novel therapeutic targets." | ( Antoniu, SA, 2008) |
| "Idiopathic pulmonary fibrosis is a lethal parenchymal lung disease characterized by denudation of the lung epithelium, fibroblast proliferation, and collagen deposition." | ( Lathrop, KL; Ray, A; Ray, P; Ray, R; Rose, JL; Shukla, MN, 2009) |
| "Pulmonary fibrosis is a progressive scarring disease with no effective treatment." | ( Ferguson, HE; Garcia-Bates, TM; Huxlin, KR; Kulkarni, A; Lehmann, GM; Phipps, RP; Sime, PJ; Thatcher, TH, 2009) |
| "Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix components in the alveolar space, which hampers normal respiration process." | ( Kalayarasan, S; Sriram, N; Sudhandiran, G, 2009) |
| "Pulmonary fibrosis is a progressive and lethal lung disease characterized by accumulation of ECM and loss of pulmonary function." | ( Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T; Tsujimura, T, 2009) |
| "IPF (idiopathic pulmonary fibrosis) is a chronic progressive disease of unknown aetiology without effective treatment." | ( Goodwin, A; Jenkins, G, 2009) |
| "Pulmonary fibrosis is an extraarticular manifestation of rheumatoid arthritis (RA), which appears between 20 to 40% of cases." | ( Gabay, C; Nendaz, M; Schaller, D, 2010) |
| "Pulmonary fibrosis is a devastating as yet untreatable disease." | ( Couegnat, M; Couillin, I; Crestani, B; Fauconnier, L; Fick, L; Gasse, P; Gombault, A; Kanellopoulos, J; Marchand-Adam, S; Quesniaux, VF; Riteau, N; Ryffel, B, 2010) |
| "Pulmonary fibrosis is defined by an overgrowth of fibroblasts and extracellular matrix deposition, and results in respiratory dysfunction that is often fatal." | ( Grutters, JC; Kazemier, KM; Korthagen, NM; Nagtegaal, MM; van den Bosch, JM; van Moorsel, CH, 2010) |
| "Pulmonary fibrosis is a type of interstitial lung disease that causes progressive scarring in lung tissues." | ( Ahn, JY; Jeong, G; Kim, MH; Lee, SL; Lim, MJ; Park, S; Song, JY; Yun, YS, 2010) |
| "Idiopathic pulmonary fibrosis is a chronic progressive lung disease with poor outcome and no effective treatment to date." | ( Balduzzi, S; Cerri, S; D'Amico, R; Del Giovane, C; Luppi, F; Richeldi, L; Spagnolo, P; Walters, EH, 2010) |
| "Pulmonary fibrosis is a progressive and lethal lung disease characterized by accumulation of extracellular matrix and loss of pulmonary function." | ( Bani, D; Bathgate, RA; Hermesh, C; Pini, A; Rotman, G; Samuel, CS; Shemesh, R; Wool, A; Zauberman, A, 2010) |
| "Pulmonary fibrosis is characterized by progressive worsening of pulmonary function leading to a high incidence of death." | ( Nakano, T; Tabata, C; Tabata, R, 2010) |
| "Idiopathic pulmonary fibrosis is the most lethal diffuse fibrosing lung disease, and is characterized by the deposition of extracellular matrix." | ( Hasegawa, Y; Hashimoto, N; Hayashi, Y; Imaizumi, K; Kawabe, T; Matsushima, M; Nakamura, T; Shibasaki, M; Shimokata, K, 2011) |
| "Idiopathic pulmonary fibrosis is regarded as a lethal chronic disease accompanied with excessive collagen disposition." | ( Chen, L; Chen, Z; Luo, Y; Ma, L; Ma, Y; Qi, B; Wang, G; Wei, X; Wei, Y; Zheng, H, 2011) |
| "Pulmonary fibrosis is a relentlessly progressive disease for which the etiology can be idiopathic or associated with environmental or occupational exposures." | ( Holland, S; Li, S; Pfau, JC; Sentissi, JJ, 2011) |
| "Idiopathic pulmonary fibrosis is a devastating disease characterized by a progressive, irreversible, and ultimately lethal form of lung fibrosis." | ( Cesta, MF; Gwinn, WM; Kapita, MC; Martin, WJ; Wang, PM, 2011) |
| "Pulmonary fibrosis is a highly heterogeneous and lethal pathological process with limited therapeutic options." | ( Wynn, TA, 2011) |
| "Pulmonary fibrosis is a potentially life-threatening disease that may be caused by overt or asymptomatic inflammatory responses." | ( Byoun, OJ; Jeong, EM; Kim, IG; Kim, YS; Kim, YW; Lee, DS; Melino, G; Oh, K; Park, HB; Shin, DM, 2011) |
| "Pulmonary fibrosis is a rare complication of oxaliplatin and capecitabine/5-fluorouracil." | ( Chan, AK; Choo, BA; Glaholm, J, 2011) |
| "Pulmonary fibrosis is a devastating disease with a poor prognosis." | ( Kiyan, E; Kiyici, A; Narin, C; Suerdem, M; Toy, H; Tulek, B, 2011) |
| "Pulmonary fibrosis is a chronic disease." | ( Ceribasi, AO; Demir, T; Kaplan, DS; Kisacik, B; Onat, AM; Pehlivan, Y; Taysi, S; Turkbeyler, IH; Tutar, E, 2012) |
| "Pulmonary fibrosis is a component of many interstitial lung diseases, including idiopathic pulmonary fibrosis, a chronic, progressive disease for which there is currently no effective therapy." | ( Kleeberger, SR; Walters, DM, 2008) |
| "Idiopathic pulmonary fibrosis is the most prevalent chronic fibrosing lung disease." | ( El-Aidy, Ael-R; Ewais, MM; Samah, M; Tawfik, MK, 2012) |
| "Idiopathic pulmonary fibrosis is a chronic, irreversible and debilitating lung disease showing fibroblast/myofibroblast expansion and excessive deposition of extracellular matrix in the interstitium leading to breathing difficulty." | ( Chan, MH; Che, CT; Chen, M; Cheung, FW; Hui, PK; Ip, SP; Ling, YH; Liu, WK, 2012) |
| "Pulmonary fibrosis is a debilitating and lethal disease with no effective treatment options." | ( Baugh, JA; Levendale, A; Neary, R; Robinson, CM; Watson, CJ, 2012) |
| "Pulmonary fibrosis is one of the most common chronic interstitial lung diseases with high mortality rate after diagnosis and limited successful treatment." | ( Awad, AS; El-Bakly, WM; El-Demerdash, E; El-Khouly, D; El-Mesallamy, HO, 2012) |
| "Pulmonary fibrosis is often complicated by pulmonary hypertension." | ( Arzt, M; Blumberg, FC; Lange, TJ; Lehmann, H; Nowrotek, A; Pfeifer, M; Schroll, S; Sebah, D; Wensel, R, 2013) |
| "Pulmonary fibrosis is characterized by an inflammatory response that includes macrophages, neutrophils, lymphocytes, and mast cells." | ( Branch-Elliman, D; Brazin, J; Jung, A; Kaner, RJ; McGee, D; O'Connor, NJ; Reid, AC; Silver, RB; Stiles, B; Summers, B; Veerappan, A; Worgall, S, 2013) |
| "Pulmonary fibrosis is a serious and irreversible lung injury with obscure etiologic mechanisms and no effective treatment to date." | ( Bai, H; Chen, H; Hai, C; Li, W; Liang, X; Liu, R; Qin, X; Wang, X; Zhang, W; Zhang, X, 2013) |
| "Idiopathic pulmonary fibrosis is a rare disorder due to progressive, widespread fibrotic damage of the lung parenchyma." | ( , 2013) |
| "Idiopathic pulmonary fibrosis is a progressive and chronic lung disease of unknown cause." | ( Kim, S; Lim, JH; Woo, CH, 2013) |
| "Pulmonary fibrosis is caused by excessive proliferation and accumulation of stromal cells." | ( Davidson, C; Edukulla, R; Hardie, WD; Ikegami, M; Madala, SK; Schmidt, S, 2014) |
| "Pulmonary fibrosis is a progressive and fatal lung disorder with high mortality rate." | ( Dang, XM; Ma, AQ; Yang, L; Zhu, B, 2013) |
| "Pulmonary fibrosis is often triggered by an epithelial injury resulting in the formation of fibrotic lesions in the lung, which progress to impair gas exchange and ultimately cause death." | ( Acciani, TH; Davidson, C; Edukulla, R; Hardie, WD; Korfhagen, TR; Lecras, TD; Madala, SK; Medvedovic, M; Phatak, M; Schmidt, S; Wagner, K, 2014) |
| "Pulmonary fibrosis is a lung disease wherein lung parenchyma is gradually and irreversibly replaced with collagen." | ( Choi, EY; Kang, YY; Kim, DY; Lee, SH, 2014) |
| "Idiopathic pulmonary fibrosis is a progressive and lethal disease, characterized by loss of lung elasticity and alveolar surface area, secondary to alveolar epithelial cell injury, reactive inflammation, proliferation of fibroblasts, and deposition of extracellular matrix." | ( Accart, N; Beckmann, N; Cannet, C; Dunbar, A; Egger, C; Gérard, C; Jarai, G; Jarman, E; Piaia, A; Schmid, HA; Tigani, B; Vidotto, N, 2014) |
| "Idiopathic pulmonary fibrosis is thought to involve lung injury caused by reactive oxygen species (ROS), which in turn is followed by abnormal fibrosis." | ( Asano, T; Azuma, A; Kurotsu, S; Mizushima, T; Niino, T; Sugizaki, T; Suzuki, H; Tanaka, K, 2014) |
| "Idiopathic pulmonary fibrosis is a progressive fatal lung disease characterized by excessive collagen deposition, with no effective treatments." | ( Chilakapati, DR; Chilakapati, SR; Manikonda, PK; Serasanambati, M; Watson, RR, 2014) |
| "Idiopathic pulmonary fibrosis is characterized by a progressive and irreversible respiratory failure." | ( Bondue, B; De Vuyst, P; Doumont, G; Egrise, D; Goldman, S; Huaux, F; Lacroix, S; Parmentier, M; Rorive, S; Sauvage, S; Sherer, F; Van Simaeys, G; Vosters, O; Yakoub, Y, 2015) |
| "Idiopathic pulmonary fibrosis is a chronic pulmonary disease that is characterized by formation of scar tissue in lungs." | ( Abdullah, M; Ho, CC; Koh, RY; Lim, CL; Seow, HF; Uhal, BD; Vidyadaran, S, 2015) |
| "Pulmonary fibrosis is a progressive and fatal disease that involves the remodeling of the distal airspace and the lung parenchyma, which results in compromised gas exchange." | ( Boylan, D; Counihan, I; Cramton, J; Donnelly, SC; Fabre, A; Gauldie, J; Kane, R; Keane, MP; Lumsden, RV; Medina, MF; O'Beirne, S; Walsh, SM; Worrell, JC, 2015) |
| "Idiopathic pulmonary fibrosis is a chronic and progressive fibrotic lung disorder with unknown etiology and a high mortality rate." | ( Feng, Z; Gao, L; He, H; Lin, H; Tang, H; Wu, T; Wu, Y, 2015) |
| "Idiopathic pulmonary fibrosis is the most devastating diffuse fibrosing lung disease of unknown aetiology." | ( Borensztajn, K; Crestani, B; Daalhuisen, J; Lin, C; Spek, CA; ten Brink, M; van der Poll, T; von der Thüsen, J, 2015) |
| "Radiation-induced pulmonary fibrosis is a common disease and has a poor prognosis owing to the progressive breakdown of gas exchange regions in the lung." | ( Chang, PY; Cui, S; Dong, LH; Jiang, X; Jiang, YY; Liu, F; Liu, YJ; Qu, C; Qu, YQ; Xia, CC, 2015) |
| "Pulmonary fibrosis is one of the most common complications of paraquat (PQ) poisoning, which demands for more effective therapies." | ( Cao, Y; He, YR; Lau, WB; Liang, ZA; Yao, R; Zeng, Z, 2015) |
| "Pulmonary fibrosis is a respiratory disease with a high mortality rate and its pathogenesis involves multiple mechanisms including epithelial cell injury, fibroblast proliferation, inflammation, and collagen coagulation." | ( Fu, Q; Li, N; Liu, T; Lv, C; Qiu, X; Sun, Y; Wang, L; Yang, D; Yuan, W, 2015) |
| "Pulmonary fibrosis is a common and dose-limiting side-effect of ionizing radiation used to treat cancers of the thoracic region." | ( Judge, JL; Kottmann, RM; Owens, KM; Phipps, RP; Pollock, SJ; Sime, PJ; Thatcher, TH; Williams, JP; Woeller, CF, 2015) |
| "Pulmonary fibrosis is a progressive and lethal disorder." | ( Guo, K; Ni, S; Pang, L; Qiu, X; Song, Z; Wang, D, 2015) |
| "Pulmonary fibrosis is a progressive disease with only few treatment options available at the moment." | ( Ayata, K; Beckert, J; Cicko, S; Grimm, M; Hossfeld, M; Idzko, M; Meyer, A; Müller, T; Zissel, G, 2015) |
| "Pulmonary fibrosis is a serious lung disorder that can lead to respiratory failure." | ( Chen, B; Chen, L; Deb, DK; Li, YC; Liu, SQ; Liu, T; Meliton, A; Shi, Y; Solway, J; Wang, J, 2015) |
| "Pulmonary fibrosis is prevalent in Paraquat (PQ) poisoning." | ( Peng, L; Xie, L; Xiong, J; You, J; Zeng, Y; Zhou, D, 2016) |
| "The pulmonary fibrosis is a common feature of several diseases and may be induced by inflammatory disorders following inhalation of organic and inorganic dusts (e." | ( Riccò, M, 2015) |
| "Pulmonary fibrosis is a common complication in these interstitial lung diseases, and PF always has a poor prognosis and short survival." | ( Hao, Y; Liu, Y, 2016) |
| "Idiopathic pulmonary fibrosis is a lethal lung disease that is characterized by the accumulation of extracellular matrix and a change in lung structure." | ( Chono, S; Tada, H; Togami, K, 2016) |
| "Pulmonary fibrosis is a chronic lung disease characterized by inflammation and collagen deposition, with an estimated mortality rate exceeding 70%." | ( Choi, HG; Hwang, HS; Lee, C; Lee, EH; Lee, ES; Lee, S; Seo, J; Thao, LQ; Youn, YS, 2016) |
| "Radiation-induced pulmonary fibrosis is a severe side effect of thoracic irradiation, but its pathogenesis remains poorly understood and no effective treatment is available." | ( Blackburn, MR; Cappuccini, F; Chen, NY; de Leve, S; Eldh, T; Fischer, U; Gau, E; Jendrossek, V; Karmouty-Quintana, H; Kasper, M; Klein, D; Meyer, AV; Ritchey, JW; Stuschke, M; Thompson, LF; Westendorf, AM; Wirsdörfer, F, 2016) |
| "IR-induced pulmonary fibrosis is one of the most severe late complications of radiotherapy for lung cancer." | ( Chen, C; Han, D; Hong, J; Ma, J; Okunieff, P; Yang, S; Zhang, L; Zhang, M; Zhang, SB; Zhang, Z, 2016) |
| "Pulmonary fibrosis is a progressive lung disorder of unknown etiology, which is characterized by alterations in alveolar epithelium function, fibroblast activation, and increased extracellular matrix deposition." | ( Chen, X; Han, X; Hu, K; Li, X; Meng, X; Shi, C; Wang, C; Xiang, Z; Zhang, K, 2016) |
| "Pulmonary fibrosis is a progressive lung disorder with high mortality rate and limited successful treatment." | ( Abuelezz, SA; Hendawy, N; Osman, WM, 2016) |
| "Idiopathic pulmonary fibrosis is a progressive, degenerative and almost irreversible disease." | ( He, S; Hu, C; Meng, Q; Ouyang, Z; Shen, Y; Sun, Y; Wang, X; Wu, X; Xu, Q; You, Q, 2016) |
| "Pulmonary fibrosis is an important adverse outcome related to inhalation exposure to MWCNTs and one that the non-animal approach should be able to assess." | ( Castranova, V; Clippinger, AJ; Halappanavar, S; Nikota, J; Rothen-Rutishauser, B; Sharma, M, 2016) |
| "Pulmonary fibrosis is a progressive and fatal disorder." | ( Chu, H; Jin, L; Liu, Q; Ma, Y; Qian, F; Ren, X; Tu, W; Wang, J; Wu, T; Wu, W; Zhou, X, 2016) |
| "Idiopathic pulmonary fibrosis is a devastating disease." | ( Bianchi, A; Crémillieux, Y; Lux, F; Raffard, G; Sanchez, S; Tassali, N; Tillement, O, 2016) |
| "Pulmonary fibrosis is characterized by excessive accumulation of connective tissue, along with activated extracellular matrix (ECM)-producing cells, myofibroblasts." | ( Ekström, G; Larsson-Callerfelt, AK; Löfdahl, A; Martina Holst, C; Müller, C; Rydell-Törmänen, K; Thiman, L; Wenglén, C; Westergren-Thorsson, G, 2016) |
| "Pulmonary fibrosis is the major limiting factor for the use of bleomycin." | ( Elmaaboud, MAA; Kabel, AM; Omar, MS, 2016) |
| "Idiopathic pulmonary fibrosis is a severe disease characterized by excessive myofibroblast proliferation, extracellular matrix and fibrils deposition, remodelling of lung parenchyma and pulmonary insufficiency." | ( Boccalini, G; Calosi, L; Durante, M; Lanzi, C; Lucarini, L; Mannaioni, G; Masini, E; Moroni, F; Pini, A, 2017) |
| "Pulmonary fibrosis is associated with irreversible, or partially reversible, airflow obstruction and ultimately unresponsiveness to asthma therapies such as corticosteroids." | ( Chauhan, PS; Dash, D; Singh, R, 2017) |
| "Pulmonary fibrosis is a progressive and fatal lung disease with limited therapeutic options." | ( Aritake, K; Ayabe, S; Kida, T; Maehara, T; Murata, T; Nakamura, T; Omori, K; Urade, Y, 2016) |
| "Pulmonary fibrosis is a life-threatening disease characterized by progressive dyspnea and worsening pulmonary function." | ( Asai, K; Hino, J; Hirata, K; Hosoda, H; Kangawa, K; Konishi, K; Kyomoto, Y; Miura, K; Miyazato, M; Nojiri, T; Okamoto, A; Tokudome, T, 2017) |
| "Pulmonary fibrosis is a devastating disease without effective treatment." | ( Bahri, S; Ben Ali, R; Fazaa, S; Gasmi, K; Jameleddine, S; Ksouri, R; Mlika, M; Serairi, R; Shlyonsky, V, 2017) |
| "Pulmonary fibrosis is common in a variety of inflammatory lung diseases, such as interstitial pneumonia, chronic obstructive pulmonary disease, and silicosis." | ( Dong, XW; Ge, LT; Guan, Y; Jia, YL; Jiang, JX; Liu, Q; Liu, YN; Sun, Y; Xie, QM; Zhao, W, 2017) |
| "Idiopathic pulmonary fibrosis is known as a life-threatening disease with high mortality and limited therapeutic strategies." | ( Dong, SH; Han, ZD; Liu, YW; Tan, HZ; Wei, F, 2017) |
| "Pulmonary fibrosis is a scaring process related to chronic lung injury of all causes." | ( Cao, J; Tao, L; Wei, W; Xie, H; Zhang, C; Zhang, M, 2017) |
| "Progressive pulmonary fibrosis is the most characteristic feature of subacute PQ poisoning." | ( Cao, Y; Li, T; Wang, N; Xin, S; Yang, X, 2017) |
| "Pulmonary fibrosis is a common outcome of a variety of pulmonary interstitial diseases, and myofibroblasts are the main culprit for this process." | ( Gao, L; Lin, H; Liu, J; Sun, W; Sun, X; Tang, H; Wang, W; Wu, T, 2017) |
| "Pulmonary fibrosis is a kind of devastating interstitial lung disease due to the limited therapeutic strategies." | ( Chu, H; Cui, J; Ding, W; Guo, G; Jiang, S; Jin, L; Liu, Q; Ma, Y; Shi, X; Shi, Y; Wang, J; Zhao, Y; Zhong, Q; Zhou, X, 2017) |
| "Pulmonary fibrosis is a chronic progressive disease with limited therapeutic options and inflammatory cytokines play important roles in the pathogenesis of pulmonary fibrosis." | ( Chen, P; Wang, A; Wang, F; Yin, Y; Zhang, M, 2018) |
| "Pulmonary fibrosis is a progressive lung disease that its pathogenic mechanism currently is incompletely understood." | ( Dong, J; Han, F; Li, F; Li, H; Liu, X; Luo, M; Qiao, X; Shi, J; Wei, J; Yang, L; Zhang, J, 2017) |
| "Pulmonary fibrosis is a progressive and often fatal lung disease characterized by fibroblast proliferation and excessive deposition of extracellular matrix." | ( Guan, S; Zhou, J, 2017) |
| "Pulmonary fibrosis is a result of an abnormal wound healing in lung tissue triggered by an excessive accumulation of extracellular matrix proteins, loss of tissue elasticity, and debit of ventilatory function." | ( Aguiar, CF; Andrade-Oliveira, V; Braga, TT; Câmara, NOS; Correa-Costa, M; Grabarz, F; Hyane, MI; Landgraf, MA, 2018) |
| "Pulmonary fibrosis is a life-threatening disease characterized by progressive dyspnea and worsening of pulmonary function." | ( Duan, JX; Guan, CX; Guan, XX; Li, P; Liu, T; Liu, YP; Mei, WX; Ouyang, DS; Sun, GY; Wan, L; Zhong, WJ; Zhou, Y, 2017) |
| "Pulmonary fibrosis is characterized by over-population and excessive activation of fibroblasts and myofibroblasts disrupting normal lung structure and functioning." | ( Bahri, S; Ben Ali, R; Jameleddine, S; Mc Entee, K; Mies, F; Mlika, M; Shlyonsky, V, 2017) |
| "Pulmonary fibrosis is a progressive fibrotic lung disease of persisting lung injury and ineffective wound repair, with poor prognosis." | ( Jiang, F; Li, B; Xue, L; Yang, Y; Zhang, Z, 2017) |
| "Radiation-induced pulmonary fibrosis is a severe complication of patients treated with thoracic irradiation." | ( Chu, SG; Doyle-Eisele, M; El-Chemaly, S; Liu, X; McDonald, J; Patino-Jaramillo, NG; Perrella, MA; Rosas, IO; Tsoyi, K; Villalba, J; Wilder, J, 2018) |
| "Pulmonary fibrosis is a late manifestation of acute respiratory distress syndrome (ARDS)." | ( Gladson, S; Karasawa, S; Nishimura, R; Shimomura, I; Suzuki, T; Tada, Y; Tatsumi, K; West, J, 2017) |
| "Pulmonary fibrosis is responsible for the both short-term and long-term outcomes in patients with acute respiratory distress syndrome (ARDS)." | ( Chen, G; Lai, R; Liang, Z; Su, X; Wang, X, 2018) |
| "Pulmonary fibrosis is the most common form of interstitial lung disease." | ( Kang, H, 2017) |
| "Pulmonary fibrosis is a progressive scarring disorder of the lung with dismal prognosis and no curative therapy." | ( Evans, IC; Maher, TM; McAnulty, RJ; Pearce, DR; Peix, L; Simpson, JK, 2018) |
| "Pulmonary fibrosis is a chronic and irreversible scarring disease in the lung with poor prognosis." | ( Judge, JL; Kottmann, RM; Nagel, DJ; Owens, KM; Phipps, RP; Rackow, A; Sime, PJ, 2018) |
| "Pulmonary fibrosis is a chronic progressive fibrosis interstitial lung disease that is characterized by inflammatory infiltration and fibrotic changes." | ( Bi, J; Cui, R; Feng, Y; Gao, W; Li, Z; Liu, C; Zhang, J, 2018) |
| "Pulmonary fibrosis is a disease with chronic inflammation and excessive collagen deposition for which there is no effective treatments." | ( Gao, Q; Jiang, W; Li, M; Li, Y; Peng, X; Xu, K; Yuan, X, 2018) |
| "Pulmonary fibrosis is a debilitating disease and is often fatal." | ( Moore, BB; O'Dwyer, DN, 2018) |
| "Pulmonary fibrosis is a progressive disorder with poor prognosis and limited treatment options." | ( Li, M; Li, R; Liu, W; Lv, C; Qu, G; Song, C; Song, X; Zhang, J; Zhao, X, 2018) |
| "Pulmonary fibrosis is a specific form of interstitial pneumonia." | ( da Silva Melo, DA; da Silva, VD; de Oliveira, JR; de Souza, RG; de Souza, TR; Dias, HB; Donadio, MVF; Dos Santos, FG; Haute, GV; Jost, RT; Krause, GC; Nuñez, NK; Pitrez, PM, 2018) |
| "Pulmonary fibrosis is a progressive and intractable lung disease." | ( Lu, YB; Tian, YX; Wang, Q; Wu, M; Wu, ZX; Zhan, TW; Zhang, WP, 2018) |
| "Pulmonary fibrosis is the most common cause of death after PQ poisoning." | ( Gao, B; He, X; Jian, X; Kan, B; Wang, H; Wang, K; Wu, Q; Xu, Q, 2018) |
| "Pulmonary fibrosis is a common outcome of various interstitial lung diseases." | ( He, Y; Jiang, Z; Liu, H; Mei, J; Shen, S; Tang, M, 2018) |
| "Idiopathic Pulmonary fibrosis is a disease with high morbidity and mortality." | ( Cao, B; Chen, H; Chen, Y; Li, W; Liu, B; Liu, T; Liu, Y; Rong, Y, 2018) |
| "Pulmonary fibrosis is a multifaceted disease with high mortality and morbidity, and it is commonly nonresponsive to conventional therapy." | ( Ahad, A; Ahmad Ansari, M; Ahmad, A; Al-Jenoobi, FI; Al-Mohizea, AM; Ali, N; Khan, A; Raish, M, 2018) |
| "Pulmonary fibrosis is a poorly understood pathologic condition." | ( Hindman, B; Ma, Q, 2018) |
| "Pulmonary fibrosis is a fatal respiratory disease that gradually leads to dyspnea, mainly accompanied by excessive collagen production in the fibroblast and myofibroblast through mechanisms such as abnormal alveolar epithelial cells remodeling and stimulation of the extracellular matrix (ECM)." | ( Chiou, TW; Chuang, HM; Harn, HJ; Ho, LI; Huang, KL; Huang, MH; Lin, SZ; Su, HL, 2018) |
| "Pulmonary fibrosis is a chronic and fatal disease of lung tissue with high incidence and mortality in the world." | ( Mao, M; Sun, L; Yan, Z; Zhang, X; Zuo, C, 2018) |
| "Drug-induced pulmonary fibrosis is associated with pulmonary hypoplasia." | ( Azuma, E; Hirayama, M; Ito, T; Iwamoto, S; Koyama, S, 2018) |
| "Diffuse pulmonary fibrosis is the major pathological change of pneumoconiosis, and its mechanism is still unclear." | ( Che, S; Liu, K; Liu, Z; Wang, H; Wang, K; Yang, H; Zhang, N; Zhou, C, 2019) |
| "Pulmonary fibrosis is the final outcome of a variety of diffuse pulmonary interstitial diseases, and it has an unclear pathogenesis." | ( Chen, PP; Deng, J; Gao, Y; Hou, DS; Luo, M; Shi, WL; Xu, SF; Yang, L, 2019) |
| "Pulmonary fibrosis is one of the most typical features of PQ poisoning, which develops from several days to weeks after ingestion." | ( Liu, Y; Wang, C; Wang, X; Xu, G; Yu, H; Zhang, G; Zhao, R, 2019) |
| "Pulmonary fibrosis is characterized by progressive and irreversible scarring of alveoli, which causes reduction of surface epithelial area and eventually respiratory failure." | ( Hashimoto, S; Inagaki, Y; Kihara, M; Kiyonari, H; Matsushima, K; Nakajima, T; Shichino, S; Shiraishi, K; Tsukui, T; Ueha, S, 2019) |
| "Pulmonary fibrosis is a progressive fibrotic lung disease with a paucity of therapeutic options." | ( Li, HP; Li, YN; Liu, YJ; Wang, XL; Yang, T; Ye, CL; Zhang, HX; Zhu, XY, 2019) |
| "Silica-induced pulmonary fibrosis is a kind of worldwide occupational disease, and there is no effective treatment at present." | ( Ji, X; Li, P; Li, Y; Liu, Y; Ni, C; Pan, H; Xu, Q; Yao, W; Yuan, J, 2019) |
| "Idiopathic pulmonary fibrosis is characterized by loss of lung epithelial cells and inexorable progression of fibrosis with no effective and approved treatments." | ( Chen, M; Dong, M; Gao, Y; Han, L; Jin, F; Li, W; Lin, H; Shi, Y; Zhou, Y; Zuo, W, 2019) |
| "Idiopathic pulmonary fibrosis is characterized by aberrant fibroblast activation and excessive collagen deposition that may eventually lead to organ dysfunction." | ( Cassali, GD; Galvão, I; Kraemer, L; Melo, EM; Rago, F; Russo, RC; Santos, RAS; Teixeira, MM, 2019) |
| "Pulmonary fibrosis is a progressive disease characterized by epithelial cell damage, fibroblast proliferation, excessive extracellular matrix (ECM) deposition, and lung tissue scarring." | ( Fang, R; Guo, Y; Jin, T; Li, F; Li, Y; Liang, H; Shan, H; Su, X; Wang, Y; Yang, R; Zhang, L; Zhao, X, 2019) |
| "Early pulmonary fibrosis is the leading cause of poor prognosis in patients with acute respiratory distress syndrome (ARDS)." | ( Cao, Y; Guo, Y; Li, Y; Liu, Y; Ping, F; Shang, J; Yao, S; Yuan, Z, 2019) |
| "Pulmonary fibrosis is a progressive and irreversible disease for which therapeutic options are currently limited." | ( Chen, J; Cheng, J; Li, L; Ma, Y; Yu, Y; Zhao, J; Zhou, L, 2019) |
| "Pulmonary fibrosis is a progressive disease characterized by structural distortion of the lungs." | ( Ard, S; Chen, B; Culligan, L; Dulin, NO; Fredberg, JJ; Guzy, R; La, J; Mutlu, GM; Orlov, SN; Park, CY; Reed, EB; Smolyaninova, LV, 2019) |
| "Pulmonary fibrosis is an irreversible lung disorder with predictable decline in lung function leading to respiratory insufficiency." | ( Bale, S; Godugu, C; Prashanth Goud, M; Pulivendala, G, 2019) |
| "Pulmonary fibrosis is characterized by fibroblasts persisting in an activated form, producing excessive fibrous material that destroys alveolar structure." | ( Fogel, DM; Michalski, J; Nunez, FJ; Ostrom, RS; Penn, RB; Rennard, SI; Schulte, NA; Toews, ML, 2020) |
| "Idiopathic pulmonary fibrosis is a lung disease with limited therapeutic options that is characterized by pathological fibroblast activation and aberrant lung remodeling with scar formation." | ( Bieler, M; Black, KE; Grasberger, P; Hariri, LP; Lin, Y; Medoff, BD; Nichols, R; Nicklin, P; Pantano, L; Probst, CK; Pronzati, G; Santos, DM; Seither, P; Spinney, JJ; Tager, AM; Wyatt, D, 2020) |
| "Pulmonary fibrosis is a prototypic chronic progressive lung disease with high morbidity and mortality worldwide." | ( Chen, X; Feng, ZL; Li, A; Lin, LG; Liu, LJ; Lu, JJ; Xiao, X; Zhang, LL, 2020) |
| "Pulmonary fibrosis is a progressive chronic inflammatory lung disease whose pathogenesis is complicated." | ( Dong, L; Lu, Y; Wang, Q; Wei, T; Wu, M; Wu, Z; Yan, Q; Zhan, T; Zhang, W, 2020) |
| "Pulmonary fibrosis is a serious respiratory disease, with limited therapeutic options." | ( Ahn, DR; Jeon, S; Kang, SJ; Kim, J; Kim, KR; Kim, S; Lee, S; Lee, YS; Thai, HBD, 2020) |
| "Idiopathic pulmonary fibrosis is a progressive-fibrosing lung disease with high mortality and limited therapy, which characterized by myofibroblasts proliferation and extracellular matrix deposition." | ( Bi, Z; Deng, R; Gao, S; Li, H; Li, S; Li, X; Liang, L; Lin, J; Liu, M; Luan, J; Ma, L; Miao, Y; Wang, M; Wang, Y; Yang, C; Yu, H; Zhou, H, 2020) |
| "Pulmonary fibrosis is a progressive chronic inflammatory disease with a poor clinical outcome." | ( Hu, Z; Li, K; Lv, X, 2020) |
| "Idiopathic pulmonary fibrosis is a debilitating lung disease." | ( Liu, Y; Qi, Y, 2020) |
| "Pulmonary fibrosis is a disease in which lung tissues become fibrous and thereby causes severe respiratory disturbances." | ( Kang, MK; Kang, YH; Kim, DY; Kim, SI; Kim, YH; Lee, EJ; Na, W; Oh, H; Oh, SY, 2020) |
| "The evolution to pulmonary fibrosis is frequent in older males and patients with comorbidities and bone marrow involvement." | ( Balzarini, L; Ferrozzi, F; Mancini, C; Marvisi, M; Ramponi, S; Uccelli, M, 2020) |
| "Pulmonary fibrosis is a fatal interstitial lung disease that is characterized by excessive accumulation of extracellular matrix (ECM) and remodeling of lung." | ( Gong, GC; Han, Q; He, JX; Luo, Q; Song, SR; Su, J; Xu, X, 2020) |
| "Pulmonary fibrosis is the end stage of many interstitial lung diseases, characterized by the deposition of excess extracellular matrix (ECM), destruction of normal alveolar structure, and resulting in the obstruction of gas exchange and respiratory failure." | ( Chen, H; Fang, L; Kong, R; Que, J, 2020) |
| "Pulmonary fibrosis is a key feature of COVID-19, Chinese herbal medicine Arenaria kansuensis has been used for curing pulmonary disease and antivirus for a long time and it has the potential against COVID-19." | ( Cui, Y; Mei, L; Tao, Y; Wang, Z; Xin, H, 2021) |
| "Pulmonary fibrosis is a chronic condition characterized by fibroblast proliferation, and the infiltration of inflammatory cells that can initiate local tissue hypoxia." | ( Kseibati, MO; Salem, HA; Sharawy, MH, 2020) |
| "Pulmonary fibrosis is a progressive disease characterized by lung remodeling due to excessive deposition of extracellular matrix." | ( Cordaro, M; Crupi, R; Cuzzocrea, S; D'Amico, R; Di Paola, R; Fusco, R; Genovese, T; Gugliandolo, E; Impellizzeri, D; Peritore, AF; Siracusa, R, 2020) |
| "Pulmonary fibrosis is a fatal chronic lung disease, leading to poor prognosis and high mortality." | ( Bai, S; He, N; Lv, C; Song, X; Wang, R; Xing, Y; Yu, F, 2021) |
| "Pulmonary fibrosis is a rapidly progressive and fatal fibrotic lung disease with high mortality and morbidity." | ( Chen, Y; Fan, M; Gao, F; Huang, D; Li, B; Sun, L; Xu, R, 2021) |
| "Pulmonary fibrosis is a disorder that can result from PQ poisoning." | ( Chen, Z; Jiang, F; Jiang, Y; Li, S; Liu, W; Wang, T, 2021) |
| "Pulmonary fibrosis is a common pulmonary interstitial disease of pathogenesis without effective drugs for treatment." | ( Li, M; Li, R; Liu, B; Lv, C; Qu, G; Shen, K; Song, X; Wang, Y; Zhang, X, 2021) |
| "Pulmonary fibrosis is an irreversible, potentially fatal disease." | ( Aruga, K; Cui, N; Ichikawa-Shindo, Y; Kakihara, S; Kamiyoshi, A; Kawate, H; Sakurai, T; Sanjo, H; Shindo, T; Tanaka, M; Wei, Y; Zhao, Y, 2021) |
| "Pulmonary fibrosis is the primary reason for mortality in patients with paraquat (PQ) poisoning." | ( Jin, W; Liu, K; Lu, J; Meng, X; Wang, R; Xie, H; Zhu, Y, 2021) |
| "Pulmonary fibrosis is an irreparable and life-threatening disease with only limited therapeutic options." | ( Jon, S; Jung, W; Keum, H; Kim, D; Kim, J; Kim, TW; Whang, CH, 2021) |
| "Idiopathic pulmonary fibrosis is a chronic, progressive, fibrotic disease." | ( Feng, F; Gu, C; Han, D; He, H; Hrovat, J; Li, J; Peng, W; Shan, J; Wang, Z; Wu, Q; Xu, Y; Yang, P; Zhou, X, 2021) |
| "Pulmonary fibrosis is a chronic progressive disease with high incidence, prevalence, and mortality rates worldwide." | ( Baltiérrez-Hoyos, R; Pina-Canseco, S; Ramírez-Hernández, AA; Reyes-Jiménez, E; Santos-Álvarez, JC; Vásquez-Garzón, VR; Velázquez-Enríquez, JM, 2021) |
| "Pulmonary fibrosis is a manifestation of the progression of interstitial pulmonary disease." | ( Dong, J; Du, W; Liu, X; Tang, Z; Yang, F, 2021) |
| "Pulmonary fibrosis is one of the most important pathological processes associated with paraquat (PQ) poisoning." | ( Chen, H; Cui, J; Gong, Y; Liu, L; Ma, Y; Tian, Y; Tong, F; Wang, J; Wang, Y; Zhang, X, 2022) |
| "Pulmonary fibrosis is a progressive interstitial lung disease with poor prognosis." | ( Ding, DL; Liu, LM; Liu, Y; Ni, JZ; Nian, SH; Shen, XB; Wang, W; Yu, LZ, 2022) |
| "Pulmonary fibrosis is an infamous sequela of coronavirus disease 2019 (COVID-19) pneumonia leading to long-lasting respiratory problems and activity limitations." | ( Choi, K; Kim, J; Kim, M; Lee, SM, 2021) |
| "The development of pulmonary fibrosis is a rare complication of the novel coronavirus disease 2019 (COVID-19)." | ( Alamoudi, A; Alnami, A; Badedi, M; Farghaly, S; Ibrahim, R; Muhajir, A; Sadhan, MH, 2022) |
| "Pulmonary fibrosis is characterized by damage to the epithelial cells and alveolar-capillary basement membrane." | ( Annam, N; Doble, M; Karlapudi, AP; Srirama, K; T C, V, 2023) |
| "Pulmonary fibrosis is regulated by transforming growth factor-β (TGF-β) and peroxisome proliferator-activated receptor-gamma (PPARγ)." | ( Choi, J; Jeong, J, 2022) |
| "Pulmonary fibrosis is a progressive fibrotic disease with a poor prognosis and has suboptimal therapeutic options." | ( Matsushima, K; Ogawa, S; Ogawa, T; Shichino, S; Ueha, S, 2022) |
| "Pulmonary fibrosis is a progressive and usually lethal pulmonary disease." | ( Dan, F; Feng, Y; Han, H; Jia-Yu, T; Min, L; Shao-Jun, L; Sheng-Xiong, T; Shu-Li, Z; Xiang-Zhi, F, 2022) |
| "Pulmonary fibrosis is a highly aggressive and lethal disease that currently lacks effective targeting therapies." | ( Fang, Y; Gao, S; Li, A; Ling, H; Liu, G; Song, C; Wang, Y; Wu, Z; Xu, Z; Yin, Y, 2022) |
| "PQ-induced pulmonary fibrosis is the main reason for respiratory failure and death." | ( Gong, N; Huang, C; Jiang, J; Xue, X, 2022) |
| "Pulmonary fibrosis is a devastating lung disease with few therapeutic options." | ( Akosman, B; Elias, JA; Herzog, EL; Kamle, S; Kim, MO; Lee, CG; Lee, CM; Lee, JH; Park, JW; Peng, XY, 2022) |
| "Pulmonary fibrosis is an important complication of subacute paraquat (PQ) poisoning." | ( Amin, F; Etemad, L; Hashemi, M; Imenshahidi, M; Moshiri, M; Roohbakhsh, A; Salmasi, Z; Shahabadi, N; Yazdian-Robati, R, 2022) |
| "Pulmonary fibrosis is a fatal lung disease characterized by progressive fibroblast proliferation and extensive extracellular matrix (ECM) deposition." | ( Chen, S; Fang, Y; Li, P; Wan, X; Xie, S; Zhao, T, 2022) |
| "Pulmonary fibrosis is the deadliest manifestation of connective tissue disease (CTD)." | ( Han, X; Li, Q; Liu, W; Sun, L; Wang, J, 2022) |
| "Pulmonary fibrosis is a life-threatening lung disorder." | ( Chen, G; Chen, M; Shao, M; Shi, Y; Wu, Z; Yang, S; Yao, R; Zheng, A, 2022) |
| "Pulmonary fibrosis is a severe disease characterized by inflammation and fibrosis of unknown etiology and lacking an effective treatment." | ( Catarinicchia, S; Jacobson, KA; Lucarini, L; Marri, S; Masini, E; Pini, A; Salvemini, D; Sgambellone, S; Tosh, DK, 2022) |
| "Pulmonary fibrosis is a chronic progressive fibrotic interstitial lung disease characterized by excessive extracellular matrix (ECM) deposition caused by activated fibroblasts." | ( Cheng, D; Li, Z; Liu, Y; Ni, C; Sun, W; Wang, Y; Xiong, H; Zhou, S, 2022) |
| "Pulmonary fibrosis is the end‑stage manifestation of wide range of respiratory diseases and during pulmonary fibrosis, pulmonary inflammation and epithelial‑mesenchymal transition (EMT) play important roles." | ( Banga, HS; Begum, G; Leishangthem, GD; Singh, ND, 2022) |
| "Pulmonary fibrosis is the end‑stage manifestation of wide range of respiratory diseases and during pulmonary fibrosis, pulmonary inflammation and epithelial‑mesenchymal transition (EMT) play important roles." | ( Banga, HS; Begum, G; Leishangthem, GD; Singh, ND, 2022) |
| "Pulmonary fibrosis is the end‑stage manifestation of wide range of respiratory diseases and during pulmonary fibrosis, pulmonary inflammation and epithelial‑mesenchymal transition (EMT) play important roles." | ( Banga, HS; Begum, G; Leishangthem, GD; Singh, ND, 2022) |
| "Pulmonary fibrosis is a major cause of the poor prognosis of acute respiratory distress syndrome (ARDS)." | ( Fang, XZ; He, YJ; Li, M; Li, RT; Reng, LH; Shang, Y; Shu, HQ; Sun, DY; Sun, MM; Wang, YX; Xu, JQ; Xu, JX; Yang, YY; Yu, Y; Yuan, SY; Zhang, P; Zhou, T, 2023) |
| "Pulmonary fibrosis is a major cause of the poor prognosis of acute respiratory distress syndrome (ARDS)." | ( Fang, XZ; He, YJ; Li, M; Li, RT; Reng, LH; Shang, Y; Shu, HQ; Sun, DY; Sun, MM; Wang, YX; Xu, JQ; Xu, JX; Yang, YY; Yu, Y; Yuan, SY; Zhang, P; Zhou, T, 2023) |
| "Idiopathic pulmonary fibrosis is a terminal lung ailment that shares several pathological and genetic mechanisms with severe COVID-19." | ( Arafa, EA; Hussein, RM; Mohamed, WR; Raheem, SA, 2023) |
| "Pulmonary fibrosis is a destructive, progressive disease that dramatically reduces life quality of patients, ultimately leading to death." | ( Araújo-Silva, CA; Benjamim, CF; Blanco, PJ; Bulant, CA; Canetti, C; Fraga-Junior, VS; Guilherme, RF; Lemos, FS; Magalhães, NS; Moraes, JA; Nogueira, TO; Pecli, C; Scharfstein, J; Serra, R; Silva, JBNF; Svensjö, E; Waclawiack, I, 2023) |
| "Pulmonary fibrosis is a progressive and fatal fibrotic lung disease and associated with a high mortality rate." | ( Cao, X; Guo, X; Han, Q; Jin, Y; Li, Q; Li, S; Liu, J; Liu, Y; Ren, G; Sun, W; Wang, X; Zhao, H, 2023) |
| "Pulmonary fibrosis is an interstitial lung disease caused by various factors such as exposure to workplace environmental contaminants, drugs, or X-rays." | ( Chao, J; Chen, M; Jiang, W; Long, M; Luo, W; Sun, Y; Wang, J; Wang, S; Yuan, M; Zhang, W; Zhou, Y, 2023) |
| "Pulmonary fibrosis is a chronic and progressive disease with limited therapeutic options." | ( Aue, A; Burkard, P; Englert, N; Friebe, A; Nieswandt, B; Rosenwald, A, 2023) |
| "The incidence of pulmonary fibrosis is on the rise, and existing treatments have limited efficacy in improving patient survival." | ( Han, X; Wang, S; Wu, W, 2023) |
| "Pulmonary fibrosis is a chronic progressive interstitial lung disease characterized by the replacement of lung parenchyma with fibrous scar tissue, usually as the final stage of lung injury like COPD." | ( Bai, G; Hou, Y; Jia, C; Liu, K; Wang, W; Zhang, M, 2023) |
| "Pulmonary fibrosis is a lethal and progressive pulmonary disorder in human beings." | ( Fu, T; Tian, H; Wang, L, 2023) |
| "Idiopathic pulmonary fibrosis is a chronic and highly lethal lung disease that largely results from oxidative stress; however, effective antioxidant therapy by targeting oxidative stress pathogenesis is still lacking." | ( Chen, C; He, W; Huang, Y; Jia, H; Kotha, S; Liu, Q; Mao, X; Ren, Y; Tong, Y; Wang, L; Yuan, H; Zheng, Z, 2023) |